The stock of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) is a huge mover today! About 515,554 shares traded hands. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has declined 24.57% since April 21, 2016 and is downtrending. It has underperformed by 29.90% the S&P500.
The move comes after 8 months positive chart setup for the $802.53M company. It was reported on Nov, 23 by Barchart.com. We have $6.61 PT which if reached, will make NASDAQ:ZIOP worth $32.10 million more.
Analysts await ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to report earnings on February, 22. They expect $-0.11 EPS, down 57.14% or $0.04 from last year’s $-0.07 per share. After $-0.11 actual EPS reported by ZIOPHARM Oncology Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) Ratings Coverage
Out of 3 analysts covering Ziopharm Oncology (NASDAQ:ZIOP), 0 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 0 are positive. Ziopharm Oncology has been the topic of 5 analyst reports since December 4, 2015 according to StockzIntelligence Inc. Wells Fargo initiated ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) on Friday, December 4 with “Underperform” rating. On Wednesday, May 11 the stock rating was maintained by Mizuho with “Neutral”. The stock has “Neutral” rating given by Mizuho on Monday, January 25. Wells Fargo upgraded ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) on Wednesday, August 10 to “Market Perform” rating. Raymond James initiated the stock with “Market Perform” rating in Thursday, June 2 report.
According to Zacks Investment Research, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.”
More news for ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) were recently published by: Fool.com, which released: “Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics” on November 03, 2016. Fool.com‘s article titled: “Better Buy: Ziopharm Oncology, Inc. vs. Intrexon Corporation” and published on October 14, 2016 is yet another important article.
ZIOP Company Profile
ZIOPHARM Oncology, Inc., incorporated on May 16, 2005, is a biopharmaceutical company. The Firm is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. The Company’s clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. The Company’s Ad-RTS-IL-12 + veledimex uses gene delivery system to produce interleukin-12 (IL-12), a potent, naturally occurring anti-cancer protein. The Company’s initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.